Efficacy and Safety of Octanorm (Cutaquig®) in Adults With Primary Immunodeficiencies With Predominant Antibody Deficiency: A Prospective, Open-Label Study

Immunotherapy - United Kingdom
doi 10.2217/imt-2020-0012
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Future Medicine Ltd